Disclosed are methods for delivering a preselected polypeptide into an aquatic animal by contacting the aquatic animal with an aqueous medium containing an isolated non-infectious, non-integrating polynucleotide encoding an immunogen, wherein the polynucleotide is operably linked to a promoter that controls the expression of the polynucleotide in the aquatic animal, and wherein expression of the polypeptide stimulates a detectable biological response in the animal. Also disclosed are methods for delivering a desired polynucleotide into an aquatic animal comprising contacting the aquatic animal with an aquatic medium containing an isolated non-infectious, non-integrating polynucleotide, wherein the polynucleotide is substantially complementary to all or a portion of a messenger RNA (mRNA) encoding a preselected polypeptide, and wherein expression of the polypeptide stimulates or represses a detectable biological response in the animal. Methods are further disclosed for delivering a preselected polynucleotide into an aquatic animal comprising contacting the aquatic animal with an aqueous medium containing an isolated non-infectious, non-integrating polynucleotide that is not in contact with a liposome or lipid carrier, wherein the polynucleotide stimulates a detectable biological response in the animal.

Seafood and fishery products are currently very popular in the United States and around the world. Per capita consumption of fishery products in the United States increased 25 percent in the 1980s (Tucker and Robinson, 1990). In 1994, each American ate an average of 15.2 pounds of seafood, of which 54 percent was imported (Harvey, 1996).
Fishery products reach the table of the consumer from three major sources: commercial harvest of wild species, recreational harvest of wild species, and aquaculture. Growing public concern for the decline in commercially important wild fish stocks and steady demand for fishery food items has enabled aquaculture to become a rapidly emerging component of the United States agricultural industry. Compared with terrestrial food animal production industries, very little is known about the health management aspects of cultured aquatic food species, especially with regard to infectious disease.
Viral and bacterial diseases in fin-fish, shellfish or other aquatic lifeforms pose a serious problem for the aquaculture industry. Owing to the high density of animals in the hatchery tanks or enclosed marine farming areas, infectious diseases may eradicate a large proportion of the stock in, for example, a fin-fish, shellfish, or other aquatic lifeforms facility. Prevention of disease is a more desired remedy to these threats to fish than intervention once the disease is in progress. Vaccination of aquatic animals is the only preventative method which may offer long-term protection through immunity.
Vaccination with inactivated or attenuated organisms or their products has been shown to be an effective method for increasing host resistance to infection by various organisms. The use of vaccines is based on the stimulation of specific immune responses within a host or the transfer of preformed antibodies. Effective vaccines have been developed for relatively few of the infectious agents that cause disease in domestic and aquatic animals. This often reflects technical problems associated with the growth and attenuation of virulent strains of pathogens.
The fish immune system has many features similar to the mammalian immune system, such as the presence of B cells, T cells, lymphokines, complement, and immunoglobulins. Fish have lymphocyte subclasses with roles that appear similar in many respects to those of the B and T cells of mammals. Additionally, the efficiency of the immune response of fish can be affected by outside stresses, as is true in mammals. However, fish, unlike mammals, display a temperature-dependent development of protective immunity in response to antigens.
A. Development of DNA Vaccines
Effort recently has been placed on the development of subunit vaccines. A subunit vaccine consists of only limited components, most commonly proteins, of an infectious agent. Subunit vaccines have the potential for achieving high levels of protection in the virtual absence of side effects. Subunit vaccines also offer the opportunity for the development of vaccines that are stable and easy to administer.
A rapidly emerging variation of subunit immunization is genetic vaccination, also called DNA-mediated or plasmid vaccination. Genetic immunization uses naked DNA to immunize the recipient. The DNA is xe2x80x9cnakedxe2x80x9d in the sense that it is free from any infectious delivery vehicle that can act to facilitate entry into the cell, such as viral particles. This approach is based on the finding that skeletal muscle cells injected with naked DNA are able to express the plasmid DNA-encoded proteins. The newly synthesized antigen can then stimulate a specific immune response composed of cytotoxic T cells, T-helper cells, and antibodies. Using such DNA vaccines, there is no longer a need to purify the pathogen or immunoprotective antigen for vaccination and no possibility of reversion to virulence because the DNA encodes a single viral protein.
DNA vaccines also overcome many of the subunit vaccine limitations, such as expensive production costs and poor immunogenicity, because they directly introduce only specific genes encoding protective proteins into the host and use the host cell protein synthesis machinery to produce the antigen in situ. Thus, immunization is accomplished by host cells taking up and expressing an inoculated polynucleotide. Moreover, genes that code for other proteins, such as regulatory molecules or hormones, can also be used to modulate the physiology of the target animal. Such proteins can also provide an anti-tumor response, or provide contraception.
The uptake of the DNA by host cells can result in the expression of a preselected antigen or antigens, thereby eliciting humoral or cell-mediated immune responses or both humoral and cell-mediated responses. The term xe2x80x9cimmune responsexe2x80x9d refers to a cytotoxic T cell response or increased serum levels of antibodies to an antigen. The term xe2x80x9cimmunizingxe2x80x9d refers to the production of an immune response in a vertebrate which protects (partially or totally) from the manifestations of infection or disease caused by an infectious agent. That is, a vertebrate immunized with a DNA vaccine will not be infected or will be infected to a lesser extent than would occur without immunization.
The elicited humoral and/or cell-mediated immune response can provide protection or protective immunity against infection by pathogenic agents such as bacteria, viruses and eukaryotic organisms (e.g., parasites). The protective humoral and/or cell-mediated immune responses then interfere with the infectivity or activity of the pathogen, or limit its spread or growth, resulting in protection against subsequent challenge by the pathogen. The immune response may also combat diseases and disorders involving cells that produce specific proteins.
The DNA is expressed by the animal cells and appears to stimulate persistent humoral and/or cellular responses without integration of plasmid into chromosomal DNA. Direct DNA administration obviates the lengthy and costly requirement for purified antigens. Moreover, the resultant prolonged antigen production in vivo approximates the immune system response following immunization with a live, attenuated virus or live recombinant vaccine without the risk of infection or the necessity of adjuvants and boosters.
DNA immunization via intramuscular injection has been shown to be effective in various animals against many viruses. For example, the immunization of guinea pigs against herpes simplex virus (HSV) type 2 infection (Bourne et al. (1996)); the immunization of mice against influenza virus (Fu et al. (1997)); the vaccination of chickens against influenza viruses (Kodihalli et al. (1997)); and mammals and avians against rotaviruses (Herrmann et al. U.S. Pat. No. 5,620,896). Daheshia et al. (1997) disclose that a single application of naked DNA encoding IL-1 0 to the cornea of animals expressing herpetic stromal keratitis resolved the lesions affecting these animals, causing lesion remission.
Thus, DNA vaccination provides a novel method to induce both humoral and/or cell-mediated immunities. The simplicity of the technology, and its ability to induce antibody (Ab) and cytotoxic T-lymphocyte (CTL) responses in animals with different genetic backgrounds, and its preclinical efficacy in a variety of disease models suggest that DNA vaccination is a useful approach for vaccine development. Additionally, the ability of DNA vaccines to induce immune responses with non-replicating material offers an alternative to live vectors or pathogens for eliciting cell-mediated immunity for those instances where such agents may present potential safety concerns. Also, because the immune response that is generated is broad based, the immune response elicited by DNA vaccination is particularly effective to protect against pathogen infection or combat cells associated with hyperproliferative diseases or autoimmune diseases.
B. Direct DNA Immunization/Transfection Administered by Injection or Particle Bombardment
In the past, methods of transferring genes into live animals in vivo required either viral vectors and/or liposome carriers containing DNA, or a receptor-mediated soluble DNA carrier system. Animals used were either fetal or newborn mice and rats, and expression was mostly found in liver and spleen. Later, direct gene injection of naked DNA or RNA into mouse skeletal muscle and into rat myocardium in vivo was performed. Other researchers found high levels of expression following direct injection of foreign genes into fish skeletal muscle. The histochemical analysis revealed that the constructs were expressed in distinct muscle cells in the injection area.
Direct injection of DNA into the somatic tissues of animals is a powerful strategy for immunization and gene therapy. The technique also provides an attractive alternative to the creation of transgenic animals that have the transgene stably incorporated into the genome. Not only is direct injection technologically simple, as it can be carried out with a hypodermic needle and syringe, but the biological effect of the gene transfer is relatively immediate. Expression of transgenes such as the cytokines interleukin 2 and 4, and transforming growth factor-xcex21, human dystrophin, the NP gene of influenza, and the reporter genes xcex2-galactosidase, firefly luciferase, and chloramphenicol acetyl transferase (CAT) has been demonstrated in animals after direct DNA injection. The technique bypasses the time-consuming selection of transgene germline carriers over several generations and its potential for effecting measurable phenotypic changes in farmed animals being examined.
In fish, biologically active foreign DNA has been delivered by electroporation and microinjection of developing embryos and sperm. Studies have demonstrated that both mammalian and fish promoters are effective in promoting the expression of foreign DNA in fish. Furthermore, the tissue specificity of expression in fish by these promoters is often similar to that observed in mammalian species. Direct injection of DNA in the muscle of tilapia fish (Oreochromis niloticus) has resulted in the expression of the reporter gene CAT, driven by the carp xcex2-actin promoter. These results indicate that transient transcription; following direct in vivo injections of a transgene into skeletal muscle, as previously measured in both mouse and rat can also be detected in fish muscle.
C. Vaccines for Aquatic Animals Administered by Injection
The introduction of novel cloned DNA sequences into fish has now become a common procedure and has an important bearing on aquaculture. To introduce recombinant DNA in fish, it is necessary to use gene constructs comprising a promoter that will drive expression of the linked protein coding sequence in the chosen fish species. Reporter genes that can be detected by simple assay procedures are routinely used to identify transformed cells. In most procedures, determination of satisfactory expression in tissues of the grown fish involves introduction of the DNA sequences into fertilized eggs by microinjection or electroporation, followed by waiting for a period of weeks or months until fish have grown to a size at which adult organs can be sampled for expression of the transgene. This delay is often necessary because expression in the embryo or fry may be problematical. A quick method of assaying for satisfactory gene promotion has recently been developed in mammals, where copies of the novel gene construct were injected directly into the muscle tissue of adult mice or rats, followed by assays on biopsy samples recovered from the site of injection. It appears that because of the special features of the muscle filament, copies find their way into intact nuclei of damaged fiber cells, and subsequent cell repair allows transient transcription of some gene copies.
It has been shown that rainbow trout will express firefly luciferase and xcex2-galactosidase from naked DNA injected into skeletal muscle. It has been demonstrated that DNA containing infectious hematopoietic necrosis virus (IHNV) glycoprotein (G) gene down-stream of the cytomegalovirus immediate early promoter (CMV-IEP) will induce an immune response in fish. Fish injected with plasmid DNA encoding the IHNV-G protein, or with a combination of plasmid DNAs encoding G protein and nucleoprotein (N) protein, produced a strong protective immune response to subsequent challenge with a lethal dose of IHNV. Expression of injected or particle bombarded reporter genes under the control of mammalian promoter sequences has been demonstrated in the common carp (Cyprinus carpio), tilapia (Oreochromis niloticus), and rainbow trout (Oncorhynchus mykiss) (Hansen et al., 1991; Rahman and Maclean, 1992; Anderson et al., 1996a; Gomez-Chiarri et al., 1996).
Research has demonstrated that genetic vaccination has elicited protective immunity in a number of different animal models, including rainbow trout (Fu et al., 1997; Kodihalli et al., 1997; Bourne et al., 1996; Anderson et al., 1996b). In some cases the protection provided by the genetic vaccine was more effective than conventional whole-virus vaccine (Kodihalli et al., 1997). While the most common route of administration of plasmid DNA is by intramuscular injection or intradermal injection, in mammals and birds mucosal absorption has also been successful (Fynan et al., 1993b). Mucosal delivery has not been shown to be effective in fish.
Few antiviral vaccines have been marketed for fish. This is largely due to the difficulty of growing virus in culture for the production of whole killed viral vaccines or safe attenuated strains of virus. Antigen-based vaccines using purified recombinant proteins are difficult and expensive to produce in large scale and may have poor immunogenicity in fish.
As with most commercially important food animals, there is a need for novel systems to vaccinate fin-fish, shellfish, and other aquatic animals against diseases. These systems should be inexpensive to produce and administer, avoid the use of live, attenuated organisms, and induce strong and long-lasting immunity preferably without boost and with induction of both antibodies and cell-mediated immunity. More preferably, the system should be applicable to very small cultured aquatic animals, be less stressful to the animals during administration, and have the capacity of simultaneously immunizing large numbers of animals for reduced labor-related costs.
The present invention relates to a method for delivering a preselected polypeptide into an aquatic animal by contacting the aquatic animal with an aqueous medium containing an isolated non-infectious, non-integrating polynucleotide that is not in contact with a liposome or lipid carrier, wherein the polypeptide is operably linked to a promoter that controls the expression of the polynucleotide in the aquatic animal, and wherein expression of the polypeptide stimulates a detectable biological response in the animal.
The present invention also provides a method for delivering a preselected polynucleotide into an aquatic animal by contacting the aquatic animal with an aqueous medium containing an isolated non-infectious, non-integrating polynucleotide that is not in contact with a liposome or lipid carrier, wherein the polynucleotide stimulates a detectable biological response in the animal.
The present invention further provides a method for inducing an immune response in an aquatic animal, comprising contacting the aquatic animal in an aqueous medium containing an isolated noninfectious polynucleotide, wherein the polynucleotide is present in a sufficient amount so that cellular uptake of the polynucleotide occurs so as to induce the immune response, and wherein the polynucleotide is not in contact with a liposome or lipid carrier.
The contacting step is preferably carried out by immersing the aquatic animal, such as a fish, either partially or fully in a solution comprising the polynucleotide. The contacting step may alternatively be performed by spraying the medium onto the animal. The medium may contain a non-lipid or liposome uptake enhancing material to facilitate entry of the polynucleotide into the cell. The medium may contain salts or nutrients for the animal.
The polynucleotide may be DNA. It may be plasmid DNA. The promoter may be a cell-specific or tissue specific promoter. Further, the DNA may be operably linked to a DNA sequence encoding a signal peptide wherein the signal peptide directs the secretion of the polypeptide in preselected cells.
The polynucleotide may be translated for a limited period of time so that the polypeptide expression is transitory. The polypeptide can be produced in vivo for at least one month, or for at least 10 days, or for less than 10 days. The polypeptide may be expressed in a therapeutic amount. The polypeptide may comprise an enzyme, a hormone, an immunomodulator, a lymphokine, a substance that manipulates reproduction, a growth promoting or growth inhibiting substance, or a substance that controls abnormal cell growth. Further, it may be an immunogen.
An advantage of prolonged synthesis of antigen is the induction of an immune response as soon as the immune system is mature. Fish may be unable to induce sufficient immune responses at a young age. For example, trout and halibut may not produce lymphoid cells until as late as ten and thirty days after hatching, respectively, and T-dependent immune responses do not appear until months after hatching. Using the methods of this invention, expression of foreign protein in fish can continue at least four months after transfection indicating that genetic immunization may be preferred for vaccination of young fish.
Aquaculture species treated by methods of this invention include a diversity of species of cultured fin-fish, shellfish, and other aquatic animals. Fin-fish include all vertebrate fish, which may be bony or cartilaginous fish. A preferred embodiment of this invention is the immunization of fin-fish. These fin-fish-include but are not limited to salmonids, carp, catfish, yellowtail, seabream, and seabass. Salmonids are a family of fin-fish which include trout (including rainbow trout), salmon, and Arctic char. Examples of shellfish include, but are not limited to, clams, lobster, shrimp, crab, and oysters. Other cultured aquatic animals include, but are not limited to eels, squid, and octopi. The polypeptide can be administered to commercially important aquatic animals such as channel catfish, salmonids, tilapia, hybrid striped bass, arctic char, carp, sturgeon, flounder, koi, angel fish, gourami, eel or crustaceans, such as shrimp, prawns, lobsters or crabs.
The present invention also provides a method for inducing an immune response in an aquatic animal, where the aquatic animal is contacted with an aqueous medium containing an isolated noninfectious polynucleotide linked to a promoter that can control the expression of the polynucleotide in the aquatic animal. The polynucleotide encodes an immunogenic polypeptide. The amount of polynucleotide is sufficient so that uptake of the polynucleotide occurs, and expression results, so as to induce an immune response in the animal. The immune response may be protective.
In this method, the polynucleotide is free from a protein coat delivery vehicle, such as a virion. The immunogen may be a viral protein or peptide, a parasite antigen, a fungal antigen, or a bacterial virulence factor, such as an inactive protein toxin or a fragment of a bacterial toxin. The polynucleotide is also free of liposomes or other lipid carriers. In other words, the aquatic animal need not be immersed in a solution of liposome formulated DNA in order for the vaccine to be effective. The medium in which the animal is immersed may contain an effective amount of an immunological adjuvant.
Also provided is a method for delivering a preselected polynucleotide into cells of an aquatic animal, comprising contacting the aquatic animal with an aqueous medium containing an isolated non-infectious, non-integrating polynucleotide encoding the polypeptide, wherein the polynucleotide is substantially complementary to all or a portion of a messenger RNA (mRNA) encoding a preselected polypeptide, and wherein the expression of the polypeptide stimulates or represses a detectable biological response in the animal. In other words, in this method, the polynucleotide may be an xe2x80x9cantisensexe2x80x9d polynucleotide.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the detailed description, and from the claims.
A. Definitions
The term xe2x80x9cpolypeptidexe2x80x9d is understood to be any translation product of a polynucleotide regardless of size, and whether glycosylated or not. Further, the term xe2x80x9cpolypeptidexe2x80x9d may be used interchangeably with the terms xe2x80x9cproteinxe2x80x9d or xe2x80x9cpeptidexe2x80x9d. Preferably, the polypeptides of the invention are biologically active. For example, a xe2x80x9cbiologically activexe2x80x9d polypeptide, subunit, or variant thereof of the invention has at least about 1%, preferably at least about 10%, more preferably at least about 50%, and even more preferably at least about 90% of the activity of a chosen polypeptide. The activity of polypeptide of the invention can be measured by methods well known to the art including, but not limited to, the ability of the polypeptide to be bound by antibodies specific for the target polypeptide, the ability of the polypeptide to elicit a sequence-specific immunologic response when the polypeptide is administered to an animal.
An isolated xe2x80x9cvariantxe2x80x9d molecule of the invention is a nucleic acid molecule or polypeptide that has at least 80%, preferably at least about 90%, and more preferably at least about 95%, but less than 100%, contiguous sequence homology or identity to the nucleotide or amino acid sequence of the corresponding wild type nucleic acid molecule or polypeptide. Moreover, a variant nucleic acid molecule or polypeptide of the invention may include nucleotide bases or amino acid residues not present in the corresponding wild type nucleic acid molecule or polypeptide, as well as internal deletions relative to the corresponding wild type molecule.
Polypeptides or variants thereof which are subjected to chemical modifications, such as esterification, amidation, reduction, protection and the like, are referred to as xe2x80x9cderivatives.xe2x80x9d For example, a modification known to improve the immunogenicity, stability and/or bioavailability of peptides in vivo is the cyclization of the peptide, for example through one or more disulfide bonds.
A xe2x80x9cbiologically activexe2x80x9d polypeptide may be an antigen derived from an infectious agent, or an antigenic fragment or polypeptide that has been experimentally determined to be immunogenic, and is preferably effective in immunizing a target animal against infection by the pathogenic agent. The preselected antigen to be expressed is designed so as to give internal, surface, secreted, or budding and assembled forms of the antigens being used as immunogens. The polynucleotide may, alternatively encode a peptide that has contraceptive or anti-cancer properties.
An xe2x80x9cimmunostimulantxe2x80x9d is an agent that stimulates the immune response. Such a molecule can stimulate any aspect of the immune response, either an innate or an adaptive immune response.
A xe2x80x9cpreselected antigenxe2x80x9d can be any antigen expressed by an infectious agent or any antigen that has been determined to be capable of eliciting an immune response, preferably a protective response against an infectious agent. These antigens may or may not be structural components of the infectious agent. The encoded antigens can be translation products or polypeptides. The polypeptides can be of various lengths. They can undergo normal host cell modifications such as glycosylation, myristoylation or phosphorylation. In addition, they can be designed to undergo intracellular, extracellular or cell-surface expression. Furthermore, they can be designed to undergo assembly and release from cells.
As used herein, the term xe2x80x9cpurifiedxe2x80x9d refers to in vitro preparation and purification of an isolated nucleic acid molecule, polypeptide or peptide of the invention, so that it is not associated with in vivo substances and is substantially free of infectious agents.
The term xe2x80x9cisolatedxe2x80x9d nucleic acid means DNA or RNA that is free of the genes and other nucleotide sequences that flank the gene in the naturally occurring genome of the organism from which the isolated DNA or RNA of the invention is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequences. xe2x80x9cPolymerase chain reactionxe2x80x9d or xe2x80x9cPCRxe2x80x9d refers to a procedure or technique in which amounts of a preselected fragment of nucleic acid, RNA, and/or DNA, are amplified as described in U.S. Pat. No. 4,683,195.
B. Immersion Delivery of Nucleic Acid into an Aquatic Animal
Genetic immunization has several advantages. The antigenic protein is synthesized in vivo giving rise to both humoral and cell-mediated (cytotoxic T lymphocytes) immune responses. However, unlike live attenuated pathogens, which also synthesize protein in vivo, DNA vaccines carry no risk of inadvertent infection. Unlike antigen-based immunization, genetic vaccination does not require the use of traditional adjuvants to generate an effective immune response. Furthermore, DNA used in the methods of this invention is inexpensive and is easy to manufacture and purify.
Genetic immunization also allows the host animal to produce foreign antigens within its own tissue thereby resulting in several advantages. One advantage is the efficient presentation of the foreign antigen to the immune system due to the expression of a protein within a self-cell, which could be an antigen-presenting cell. Another advantage is the correct folding, protein modification, and disulfide bonding of a protein expressed in a host cell, especially for viral proteins, which are normally produced in cells of hosts. Recombinant viral proteins synthesized in bacterial or yeast cells may be incorrectly post-translationally modified and are often massed in inclusion bodies, which make the proteins difficult to purify or ineffective if administered in unpurified form.
Immune responses in fish are temperature dependent. Antigen-based vaccines may give rise to sub-optimal immune responses if such vaccines are given at the wrong temperature. Genetic immunization is advantageous because expression of the antigenic protein could continue over a long period until such time as to stimulate an immune response when the temperature is optimal.
The present invention describes a new process by which aquatic animals can be vaccinated by exposure to a solution comprising nucleic acid molecules. To practice the present invention, a naked polynucleotide is prepared which operatively codes for a preselected biologically active polypeptide for incorporation into aquatic animal cells. The polynucleotide is then administered to the animal by immersing the animal in a medium containing the polynucleotide. The polynucleotide may enter cells of the epithelium of the skin, the gills or the gut wall. The polynucleotide may then be expressed in these transfected cells leading to induction of appropriate immune responses in regional or systemic lymphoid tissue. Alternatively, the polynucleotide itself may induce the biological response. For example, it may be an immunostimulant.
The immersion route of delivery is unique for aquatic animal species because of the liquid aqueous environment. The nucleic acid molecules of the present invention directly transfect the cells of fish, or other aquatic animals, and are capable of expressing an infectious disease protective antigen, immunomodulating protein, reproductive hormone, or growth hormone. It is believed that this process will have great utility in the growing aquaculture industry.
Prior research in DNA immunization with aquatic animals only used injection and particle bombardment as modes of administration because of the perception that the DNA molecules that comprise the vaccine will be degraded in the immersion bath before adequate DNA uptake is achieved by the aquatic animal. This logic is expressed by Gomez-Chiarri and co-workers (1996) in their discussion of particle bombardment is a more effective means of DNA delivery, in trout, than intramuscular injection, in which they state that much of the DNA following an intramuscular injection is degraded in the intracellular space before it is taken up by the muscle cells.
It was previously thought that muscle cells were unique among cell types in their capacity to take up and express free DNA, although one group of researchers were able to effectively immunize mice against the influenza virus by using particle bombardment of the epidermis (Fynan et al. 1993). Further, when other researchers attempted to inject DNA into the gills and the peritoneum of trout, no expression was observed in tissue lysates from these fish when they were sacrificed two days after injection. Thus, it was not expected that foreign DNA would be taken up by gill tissue and expressed.
Moreover, previous patents granted for genetic vaccines in mammals do not disclose or suggest the immersion route of DNA delivery, but only disclose parenteral and topical delivery methods. Therefore, the effectiveness of this DNA delivery process was unexpected and provides significant utility in vaccinating large numbers of often very small cultured aquatic animals.
A variety of infectious disease agents are currently a problem in the aquaculture industry. By identifying protective antigens associated with these various agents, immersion genetic vaccination will help improve production yields in aquaculture facilities. Methods of this invention may be useful in the immunization of aquaculture species against various pathogens, such as viruses, bacteria, parasites or fungi. For example, the group of pathogens includes but is not limited to hemorrhagic septicemia virus, infectious hematopoietic necrosis virus, infectious pancreatic necrosis virus, virus causing spring viremia of carp, channel catfish virus (Herpesvirus ictaluri), grass carp hemorrhagic virus, nodaviridae such as nervous necrosis virus or striped jack nervous necrosis virus, infectious salmon anaemia virus, Aeromonis salmonicida, Renibacterium salmoninarum, Yersinia, Pasteurella (including piscicida), Vibrosis (including anguillarum and ordalii), Edwardsiella (including ictaluri and tarda), Streptococci, and Ichthyophthirius.
Channel catfish culture is one of the largest aquatic agriculture industries in the United States. Two examples of infectious disease agents that may be controlled by genetic immunization are channel catfish virus (CCV) and the bacterium Edwardsiella ictaluri. Strong catfish cellular immune responses are required for adequate protection against both of these agents and immunization with CCV envelope glycoproteins (Davison and Davison, 1995) E. ictaluri chondroitinase-like enzymes (Stanley, et al., 1994), or other pathogen gene products may provide disease protection. Additionally, protozoan parasite disease, such as Ichthyopthirium multifiliis, may be controlled by this invention.
The salmonid culture industry is also threatened by a variety of viral and bacterial infectious agents. Infectious hematopoietic necrosis virus, infectious pancreatic necrosis virus, onchorhynchus masou virus, viral hemorrhagic septicemia, and herpesvirus salmonis, and infectious salmon anemia virus are viral agents that cause high mortality in susceptible fish (Heppell, et al., 1995; Bouchard et al., 1998). Bacterial pathogens responsible for high morbidity and mortality in salmonid aquaculture include Aeromonas salmonicida, Vibrio anguillarum, Yersinia ruckerii, and Renibacterium salmoninarum (Stoskopf, 1993; Hirst and Ellis, 1994).
Other food fish species are currently used in culture operations around the world. Some examples of these fish include: tilapia, hybrid striped bass, arctic char, carp, eel, and various other species. While disease agents for less well-known aquaculture species are less well understood, the present invention can deliver immunogenic proteins, preferably for preventative genetic-based therapeutics.
As more species of ornamental fish are grown in captivity, infectious diseases associated with their culture will become more of a problem. Examples of these agents include Flavobacterium columnare, herpesvirus carpio, spring viremia of carp virus, cichlid iridovirus, lymphocystis, and various protozoan parasites (Stoskopf, 1993).
Infectious disease is one of the biggest problems in the shrimp culture industry. White spot virus, taura syndrome, and yellowhead virus are examples of important viral agents in shrimp aquaculture. The pathogen Vibrio parahaemolyticus is an example of a bacterial agent that causes disease in culture shrimp (Mikulski et al., 1998). Unfortunately, shrimp do not have a memory component to their immune system. Vaccination in the true sense of the term is not possible for invertebrates, but innate immunity may be enhanced with the use of specific pathogen antigens. These antigens, delivered by this invention may enhance the shrimp defense mechanisms and enable better yields for the producer.
Enhancing defense mechanisms in aquatic animals may also be accomplished by immersion DNA vaccination. Cytokines that modulate the immune response in aquatic organisms have been identified (Francis and Ellis, 1994; Tamai et al., 1993; Daheshia et al., 1997). By constructing plasmids that express these immunomodulators, and administering them alone or in combination with specific antigen plasmid constructs, immunity in aquatic animals may be enhanced (Francis and Ellis, 1994). Immunomodulation, therefore, may help innate defenses in organisms, such as shrimp, that lack a specific, memory-driven immune system. Moreover, growth-enhancing proteins may be delivered to the organisms by immersion DNA vaccination. These gene products will increase the growth efficiency of cultured aquatic food animals (Cho et al., 1993; Johnsson and Bjoemsson, 1994; Siharath et al. 1995).
The polynucleotide that encodes an immunogenic peptide, polypeptide or protein is directly administered to an animal in vivo. The polynucleotide encodes a polypeptide that shares at least one epitope with an immunogenic protein to be targeted. The polynucleotide is expressed by the individual""s cells to form immunogenic target proteins that elicit an immune response that is broad based.
There are numerous advantages for the use of polynucleotides for immunizations. For example, immunization can be accomplished using any antigen encoded by a polynucleotide. Furthermore, the polynucleotide encoded antigens are expressed as xe2x80x9cpurexe2x80x9d antigens in their native states and have undergone normal host cell modifications. Also, polynucleotides are easily and inexpensively manipulated and are stable as a dry product or in solution over a wide range of temperatures. Thus, this technology is valuable for the development of highly effective subunit vaccines.
The naked polynucleotide materials used according to the methods of the invention comprise DNA sequences or DNA sequences coding for polypeptides that have useful therapeutic applications. These polynucleotide sequences are naked in the sense that they are free from any infectious delivery vehicle that can act to facilitate entry into the cell. For example, the polynucleotide sequences are free of virions, which are infectious viral particles.
The DNA sequences may be used in conjunction with an uptake enhancing material, i.e., a non-infectious material that promotes transfection, such as transfection-facilitating proteins, or precipitating agents such as CaPO4.
The DNA sequences used in these methods can be those sequences which do not integrate into the genome of the host cell. These may be non-replicating DNA sequences, or specific replicating sequences genetically engineered to lack the genome-integration ability.
The polynucleotide sequences of the invention are DNA or RNA sequences having a biological, preferably a therapeutic, effect after being taken up by a cell. Examples of polynucleotides that are themselves therapeutic are anti-sense DNA and RNA or DNA coding for tRNA or rRNA to replace defective or deficient endogenous molecules. The polynucleotide of the invention can also code for therapeutic polypeptides. Therapeutic polypeptides include as a primary example, those polypeptides that can compensate for defective or deficient species in an animal, or those that act through toxic effects to limit or remove harmful cells from the body.
Polynucleotide sequences of the invention preferably code for therapeutic or immunogenic polypeptides, and these sequences may be used in association with other polynucleotide sequences coding for regulatory proteins that control the expression of these polypeptides. The regulatory protein can act by binding to genomic DNA so as to regulate its transcription; alternatively, it can act by binding to messenger RNA to increase or decrease its stability or translation efficiency.
By the term xe2x80x9coperably linked to transcriptional and translational regulatory sequencesxe2x80x9d is meant that a polypeptide coding sequence and minimal transcriptional and translational controlling sequences are connected in such a way as to permit polypeptide expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s). In the present invention, polypeptide expression in a target aquatic animal cell is particularly preferred.
The polynucleotide material delivered to the cells in vivo can take any number of forms, and the present invention is not limited to any particular polynucleotide coding for any particular polypeptide. Plasmids containing genes coding for a large number of physiologically active peptides and antigens or immunogen have been reported in the literature and can be readily obtained by those of skill in the art.
The polynucleotide can encode one or multiple antigens, such as antigens from two or more different viral proteins. Alternatively, the polynucleotide may contain one or more different DNA sequences, one sequence encoding an antigen and the others encoding polypeptides which may or may not be antigenic. For example, the vector may encode two antigens from the same pathogen. Alternatively, the different antigen(s) may induce an immune response against a different pathogen and thus serve as a multivalent vaccine. In another embodiment, the other polypeptides may serve to enhance an immune response against a targeted pathogen (e.g., helper epitopes, cytokines, carrier polypeptides, cholera toxin subunits, or other immunostimulants).
The polynucleotide can additionally be inserted into a vector that includes sequences for expression of the polynucleotide. When two or more polypeptide encoding DNA sequences are present in one vector, the transcription of each antigen-encoding DNA sequence may be directed from its own promoter for expression of two or more non-fused polypeptides. Alternatively, one promoter may drive the expression of two or more antigen-encoding DNA sequences joined in frame to each other to express a fusion protein. For example, VP2 and VP3 proteins of infectious pancreatic necrosis virus (IPNV) may be fused. In another embodiment, DNA sequences encoding two or more antigens from different diseases may be joined to form a multivalent vaccine when expressed.
Alternatively, a DNA sequence encoding an antigenic polypeptide may be fused to a DNA sequence encoding a carrier polypeptide. In a preferred embodiment, the carrier polypeptide may contain one or more envelope proteins of the hepatitis B virus, preferably from the human hepatitis B virus. In a more preferred embodiment, the envelope proteins of hepatitis B virus will be the small and major protein (also referred to as surface antigen).
Alternatively, the DNA sequences encoding additional antigens may be administered by using a second vector containing such sequences. Such sequences may encode antigens from the same pathogen or different pathogens, or cytokines, cholera toxin subunits, or other immunostimulants. Such a vector may be administered concurrently or sequentially with the first expression vector. One vector may be induced to express protein simultaneously with or after expression of protein from the other vector.
In yet another embodiment of this invention, antigen-expressing vectors may be administered concurrently with an aptigen-based vaccine such as a recombinant protein or whole-killed vaccine. In a preferred embodiment, the antigen-expressing vector is administered simultaneously with a protein antigen (i.e., recombinant protein or whole killed pathogen). Another preferred embodiment would be to first administer a DNA vaccine to prime the immune response followed by administration of the protein antigen two to eight weeks later, preferably orally or by immersion, to boost the immune response.
The polynucleotide can be administered to an animal in the presence of adjuvants or other substances that have the capability of promoting nucleic acid uptake or recruiting immune system cells to the site of the inoculation. It should be understood that the polynucleotide itself is expressed in the host cell by transcription factors provided by the host cell, or provided by a DNA transcription unit.
According to the methods of the invention, both expressible DNA and mRNA can be delivered to cells to form a polypeptide translation product therein. If the nucleic acids contain the proper control sequences, they will direct the synthesis of relatively large amounts of the encoded protein. When the DNA and mRNA delivered to the cells codes for an immunizing peptide, the methods can be applied to achieve improved and more effective immunity against infectious agents, including intracellular viruses, and also against tumor cells.
One particularly attractive aspect of the invention is a method for obtaining long term administration of a polypeptide to an animal, comprising the step of introducing a naked DNA sequence operatively coding for the polypeptide interstitially into tissue of the animal, whereby cells of the tissue produce the polypeptide for at least one month or at least 3 months, or even at least 6 months.
Another method according to the invention is a method for obtaining transitory expression of a polypeptide into an animal, comprising the step of introducing a naked mRNA sequence operatively coding for the polypeptide interstitially into tissue of the animal, whereby cells of the tissue produce the polypeptide for less than about 20 days, usually less than about 10, days, and even less than 3 or 5 days.
The tissue into which the polynucleotide is introduced can be a persistent, non-dividing cell. The polynucleotide may be either a DNA or RNA sequence. When the polynucleotide is DNA, it can also be a DNA sequence which is itself non-replicating, but is inserted into a plasmid, and the plasmid further comprises a replicator. The DNA may be a sequence engineered so as not to integrate into the host cell genome. The polynucleotide sequences may code for a polypeptide which is either contained within the cells or secreted therefrom, or may comprise a sequence which directs the secretion of the peptide.
The dosage of the immunogenic polypeptide can be readily determined by a clinician or veterinarian employing animal models or other test systems that are well known to the art. Formulations will contain an effective amount of the DNA in an aqueous solution. The amount of DNA to be administered depends upon factors such as the age, weight and physical condition of the animal considered for vaccination. The amount of DNA also depends upon the capacity of the animal""s immune system to synthesize antibodies, and the degree of protection desired. Effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves. The subject is immunized by administration of the DNA in one or more times. Multiple administrations may be required to maintain a state of immunity by the animal to a particular pathogen.
Such DNA vaccines are stable, easy to administer, and sufficiently cost effective for widespread distribution. Administration of the DNA vaccines of the invention provide in the aquatic animal an immune response or protective immunity to disease caused by the infection.
C. Polynucleotides Delivered into Aquatic Animals
The polynucleotides used for transforming an aquatic animal may be circular or linear, double-stranded of single-stranded. Generally, the polynucleotide is DNA in the form of a plasmid and contains coding regions of beneficial DNA with flanking regulatory sequences which serve to promote the expression of the protein in the aquatic animal. xe2x80x9cHeterologous polynucleotidesxe2x80x9d is used herein to include all synthetically engineered or biologically derived polynucleotides that are introduced into an aquatic animal by a human by genetic engineering, including but not limited to, non-animal genes, modified genes, synthetic genes, portions of genes, as well as polynucleotides from fish and other aquatic animals.
The compositions of and method for constructing heterologous polynucleotides for successful transformations of animals is well know to those skilled in the art, and the same compositions and methods of construction may be used to produce the polynucleotides useful herein. The specific composition of the polynucleotide is not central to the present invention and the invention is not dependent upon the composition of the specific transforming polynucleotide used. Suitable components of the polynucleotide including promoters, polyadenylation sequences, termination signals, splicing signals, selectable markers, reporter genes, enhancers, viral replicons, introns, and bacterial plasmid sequences are well known in the art. Sambrook et al. (1989) provides suitable methods of heterologous polynucleotide construction.
Polynucleotides can be produced by a number of known methods. For example, DNA encoding a preselected antigen can be inserted into an expression vector (see, for example, Sambrook et al. (1989)). With the availability of automated nucleic acid synthesis equipment, DNA can be synthesized directly when the nucleotide sequence is known, or by a combination of PCR, cloning, and fermentation. Moreover, when the sequence of the preselected polypeptide is known, a suitable coding sequence for the polynucleotide can be inferred.
When the polynucleotide is mRNA, it can be readily prepared from the corresponding DNA in vitro. For example, conventional techniques use phage RNA polymerases SP6, T3, or T7 to prepare mRNA from DNA templates in the presence of the individual ribonucleoside triphosphates. An appropriate phage promoter, such as a T7 origin of replication site is placed in the template DNA immediately upstream of the gene to be transcribed. Systems using T7 in this manner are well known, and are described in the literature.
Generally the polynucleotides will be relatively small, i.e., less than about 30 kb to minimize any susceptibility to physical, chemical or enzymatic degradation which is known to increase as the size of the polynucleotide increases.
Suitable polynucleotides for use herein includes all polynucleotides which may provide for, or enhance, a beneficial feature of the aquatic animal. For example, the polynucleotides may encode proteins or antisense RNA transcripts in order to promote increased food values or disease resistance.
The polynucleotides to be introduced into the aquatic animal further will generally contain either a selectable marker of a reporter gene or both to facilitate identification and selection of transformed animals. Alternatively, the selectable marker may be carried on a separate piece of DNA and used in a co-transformation procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in aquatic animals. Reporter genes which encode for easily assayable marker proteins are well known in the art. In general, a reporter gene is a gene which is not present or expressed the recipient organism or tissue and which encodes a protein whose expression is manifested by some easily detectable property, e.g., phenotypic change or enzymatic activity. Examples of such genes include the chloramphenicol acetyl transferase gene from Tn9 of E. coli, and the luciferase genes form firefly Photinus pyralis.
Where the polynucleotide is DNA, promoters suitable for use in various animal systems are well known. Promoters useful herein include any constitutive, inducible, tissue or organ specific, or developmental stage specific promoter which can be expressed in the particular aquatic animal. Suitable promoters are described in the prior art. In one embodiment, the DNA sequence includes a cell-specific promoter that permits substantial transcription of the DNA only in predetermined cells. The DNA may also code for a polymerase for transcribing the DNA, and may comprise recognition sites for the polymerase.
A polynucleotide operatively codes for a polypeptide when it has all the genetic information necessary for expression by a target cell, such as promoters and the like. The terms xe2x80x9cpromoterxe2x80x9d or xe2x80x9cpromoter sequencexe2x80x9d herein refers to a minimal sequence sufficient to direct transcription. A DNA polynucleotide sequence is commonly bounded by an initiation site and a termination site to form a DNA transcription unit, and is transcribed to produce a primary transcript.
Other elements such as introns, enhancers, polyadenylation sequences and the like, may also be present on the DNA. Such elements may or may not be necessary for the function of the DNA, although they can provide a better expression of functioning of the DNA by affecting transcription, stability of the mRNA, or the like. Such elements may be included in the DNA as desired to obtain the optimal performance of the transforming DNA in the aquatic organisms. Also included in the invention is an enhancer sequence which may or may not be contiguous with the promoter sequence. Enhancer sequences influence promoter-dependent gene expression and may be located in the 5xe2x80x2 or 3xe2x80x2 regions of the native gene. Expression is constitutive or inducible by external signals or agents. Optionally, expression is cell-type specific, tissue-specific, or species specific.
To determine whether a particular combination of DNA and recipient aquatic organism are suitable for use herein, the DNA may include a reporter gene. An Assay for expression of the reporter gene may then be performed at a suitable time after the DNA has been introduced into the recipient organism.
D. Polynucleotide Delivery Process
Using the method of the present invention, the target aquatic animal is contacted with a medium containing an isolated non-infectious, non-integrating polynucleotide encoding the polypeptide. The contacting step may be performed by spraying the medium containing the polynucleotide onto the organism one or more times. Alternatively, the contacting step may be carried out by either partially or fully immersing the aquatic animal in the medium containing the polynucleotide. For example, only the head portion of the organism including the gills may be immersed into the medium. The organism may be immersed in the medium briefly, for example for about 1 to 30 seconds, or for a longer period of time, for example for about 1 to 60 minutes, preferably for about 30 minutes. The organism may alternatively be immersed in the medium for about 3 hours to several weeks.
The medium is an aqueous solution containing the polynucleotide. The medium can also contain a non-lipid or liposome uptake enhancing material and/or nutrients and salts suitable for the target organism.

Delivery of nucleic acid into aquatic animals

University of Georgia Research Foundation, Inc.


A fall protection lanyard apparatus for use in transferring loads in an elevated environment is disclosed. The fall protection lanyard may be connected to a load and used to safely transfer a human or nonhuman load in an elevated environment, such as from an airborne rotorcraft to an adjacent structure while providing fall protection for the load and emergency release capabilities for the aircraft. The lanyard apparatus provides total fall protection for the load throughout the transfer process without restricting or otherwise limiting available emergency flight options/maneuvers by incorporating an emergency release that automatically activates on demand. In a preferred embodiment, the fall protection lanyard apparatus includes first and second load-bearing lanyards, each terminating in a free end incorporating a connectable hook. The competing concerns of fall protection (for the load) and on-demand emergency release (for the aircraft) are each enabled by providing the first lanyard with an automatic quick release mechanism activated by a predetermined threshold force applied across the lanyard apparatus. The lanyard apparatus provides total fall protection during the transfer of a load to a structure in any elevated environment while providing an on-demand quick-release in emergency situations.

N/A
N/A
A portion of the disclosure of this patent document contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or patent disclosure as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyrights.
1. Field of the Invention
The present invention relates generally to safety devices used for in fall protection, and, more particularly, to lanyard apparatus for use in providing fall protection for a load in an elevated environment.
2. Description of the Background Art
There are a number of basic devices, such as safety harnesses, for use in providing fall protection for loads in elevated environments. Safety harnesses, for example, commonly consist of shoulder straps attached to a waist or chest belt. Some harnesses incorporate suspender style straps with a tether point-of-attachment on the front center of the chest/waist strap. Others comprise a Y-shaped design, where the shoulder straps aare connected to a strap extending vertically from the waist belt to form a three-point intersection. These harnesses are typically constructed of nylon webbing, and commonly include padding. The harness is designed to support the load (i.e., body weight) by the torso and shoulders of the user for suspension from a helicopter. Sit harnesses comprise another category of HEL devices. Also known as pelvic harnesses, bosun""s seat, rescue harnesses or rigger""s harnesses, these devices suspend the user in a seated posture. The basic design of a sit harness includes a waist belt connected to leg loops routed around the top of the thighs. The point of the tether attachment typically extends directly in front of the upper pelvic region. Full-body harnesses (FBHs) comprise a combination of sit harnesses and chest harnesses. While there are a number of variations of the basic design of the harness, all full-body harnesses include leg loops, shoulder straps, and either a waist belt, a chest belt, or both.
One application wherein such safety devices are used involves the use of rotary winged aircraft, such as helicopters, in external load transfer operations. For example, human external load operations (HEL) typically involve the transportation of a passenger suspended by a cable assembly under the helicopter. For example, helicopters equipped with load suspension points, or hooks, are commonly used to transport loads in sling configuration wherein the load is suspended beneath the helicopter by a suspension apparatus. In other applications, helicopters carry cargo as well as human loads in various configurations external to the fuselage, such as on the skids or on skid-mounted platforms. For example, load-bearing platforms may be affixed to the helicopter to permit persons to operate external to the crew compartment. In other situations, a person may stand on one of the helicopter landing skids and operate in the external environment. HEL operations are commonly performed in transmission line maintenance and repair procedures in the electrical power industry, in the logging industry to access remote work sites, and for emergency rescue operations.
The present inventor has contributed significantly to safety advances in helicopter external load operations, particularly external human load operations. My U.S. Pat. No. 4,673,059 discloses a method and system for placing a load, which may consist of a combination of personnel and equipment, on or in proximity to components of an energized power transmission line. My U.S. Pat. No. 5,417,304 discloses a method for suspending a load from a rotary winged aircraft, such as a helicopter, using an apparatus that incorporates an emergency release activated by the suspended person.
In certain situations, however, it is necessary or desirable to transfer external loads from a hovering helicopter to a structure, such as a power transmission tower or an energized or de-energized power transmission line, ground wire, or other elevated point or structure. Neither the methods disclosed in the ""059 and ""034 patents, nor the background art, discloses a suitable safety apparatus for accomplishing the transfer of an external load from a hovering helicopter to an elevated stricture while maintaining adequate safeguards for both the helicopter as well as the load.
While my ""304 patent discloses an emergency release for use with a suspended load, the system disclosed therein is a release-on-command type system that requires the suspended person to: (1) realize the existence of an emergency with the helicopter; and (2) manually activate the quick release to permit the helicopter to pull away. As should be apparent, the primary concerns in such human transfer applications involve maintaining adequate fall protection for the person during the transfer procedure without limiting helicopter operations, particularly the availability of emergency maneuvers and operations. It Is critical to maintain full fall protection for the person through the entire transfer process, while, at the same not limiting the operation of the helicopter in emergency situations.
Currently, there is little standardization and a general lack of safety procedures practiced by those performing HEL operations. While regulations exist regarding the physical and structural characteristics of external load operations, little consideration has been given to the issue of humans as external loads. Federal Aviation Regulations applicable to rotorcraft operations, particularly those referring to human external loads, are found in Title 14 of the Code of Federal Regulations (CFR). The collection of FAA regulations found in 14 CFR is often referred to as the Federal Aviation Regulations (FARs). Within 14 CFR, part 133 pertains directly to rotorcraft external load operations and contains subparts that address applicability, certification rules, operating rules, and related requirements. In addition, part 27 requires that any external load attaching means must include a quick-release system to enable the pilot to release the external load quickly during flight. While the regulations address a number of areas, they provide no specific detail regarding the attachment method, human load transfer methods, or the structure or function of quick-release devices.
As a result of the lack of adequate safety methods there have been a number of rotorcraft accidents in connection with HEL operations. During the period from 1973 through 1995, it has been reported that there were 473 external load operations in which the helicopters were involved in either an accident or an incident. Of the 473 accidents listed, a substantial number involved operations using a sling line or sling load. Accordingly, it is recognized that the predominant cause of external load accidents involves problems with the sling line/load.
One common, yet inherently risky prior art method of transferring an external human load from a hovering helicopter to a structure, in a non-sling configuration, consists of bringing the helicopter to a hover immediately adjacent to a structure, wherein the helicopter may be stabilized by the placement of one or both skids (or wheels) on the structure, thereby allowing the person to step from the helicopter to the structure. This method, however, is significantly flawed in that, to avoid tethering the helicopter to the structure and thereby limiting the availability of emergency flight procedures (e.g. emergency pull-away), there exist periods of time during the transfer that the person is without fall protection, and consequently at substantial risk.
Thus, although HEL operations have been practiced, there remains a need a safety lanyard apparatus for use in providing fall protection for loads in an external environment. More particularly there exists a need for an improved safety lanyard for use in HEL operations which is adapted to provide total fall protection for the load while preserving emergency operating procedures for the helicopter and crew by incorporating an emergency quick release.
The present invention addresses the shortcomings of the background art by providing a fall protection lanyard apparatus for use in transferring loads in an elevated environment. The fall protection lanyard may be connected to a load and used to transfer the load from an airborne rotorcraft to a structure while providing fall protection and emergency release capabilities for the aircraft. The lanyard apparatus provides total fall protection for the load throughout the transfer process without restricting or otherwise limiting available emergency flight options/maneuvers by incorporating an emergency release that automatically activates on demand.
In a preferred embodiment, the fall protection lanyard apparatus includes first and second load-bearing lanyards, each terminating in a free end incorporating a hook. The competing concerns of fall protection (for the load) and on-demand emergency release (for the aircraft) are each enabled by providing the first lanyard with a quick release mechanism and the second lanyard with a limited slip mechanism.
Each lanyard is preferably attached to a common point, such as a load bearing steel O-ring, which in turn is attached to a safety harness which secures the load. The first lanyard incorporates a quick-release mechanism, which, upon activation, results in the separation of the hook and free end portion thereof. The second lanyard incorporates a limited slip mechanism, which, upon application of a predetermined force thereon, activates the first lanyard""s quick-release mechanism. The lanyard apparatus provides total fall protection during the transfer of a load to a structure in any elevated environment while providing an on-demand quick-release in emergency situations.
The lanyard apparatus may be used to transfer of the load from the hovering aircraft to an adjacent structure by: (1) attaching the free end of the first lanyard to the helicopter; (2) attaching the free end of the second lanyard to the structure; (3) detaching the first lanyard from the helicopter; and (4) depositing the load onto the structure. When transferring from the structure to the helicopter the method is essentially reversed. When transferring loads as described, fall protection is provided since the load is safely tethered to a load bearing structure at all times. In addition, a quick release mechanism may be used to simultaneously provide an emergency release that allows the aircraft to instantly pull away without placing the external load at risk.
Accordingly, it is a primary object of the instant invention to provide an improved fall protection device.
Another object of the present invention is to provide a fall protection apparatus adapted to provide comprehensive fall protection for a person or thing in an elevated environment.
Still another object of the present invention is to provide a safety apparatus that provides fall protection for a human external load engaged in an airborne transfer, before, during, and after transfer to a structure.
Yet another object of the present invention is to provide a fall protection system for HEL operations that provides an emergency release for a helicopter tethered to a structure while transferring human and non-human loads to or from the structure.
Still another object of the present invention is to provide a fall protection system for HEL operations that permits for release of a tethered helicopter while transferring a load to or from the structure.
Another object of the present invention is to provide an apparatus for use in transferring loads from a hovering rotorcraft to a structure while providing total fall protection and incorporating an emergency release that does not require activation by the person being transferred.
In accordance with these and other objects, which will become apparent hereinafter, the instant invention will now be described with particular reference to the accompanying drawings.


There are many lung diseases and conditions for which the preferred form of treatment involves delivering a medicament of the appropriate sort down the Patient""s airways into the lungs themselves. The most effective treatments involve the inhalation as an aerosol of some suitable agent in normally inhaled air, and it will often be the case that it is best to deliver the agent as a xe2x80x9cspikexe2x80x9d or short pulse at some selected point within the Patient""s breathing cycle.

This invention relates to inhalers, and concerns in particular medical inhaler apparatus for use in the treatment of certain lung diseases or conditions.
In the Specification of British Patent Application No: 2,283,179 (which corresponds to published PCT International Application WO 95/10,315) there is described and claimed a novel method, and associated apparatus, for the use of nitric oxide in the treatment of various lung conditions and diseases. The present invention relates to improved apparatus which can be used not only for this purpose but also in the treatment of other lung problems.
There are many lung diseases and conditionsxe2x80x94suffered both by humans and by other animalsxe2x80x94for which the preferred form of treatment involves delivering a medicament of the appropriate sort down the Patient""s airways into the lungs themselves, where the medicament can act upon, and perhaps be absorbed into, the tissues of the lungs. One such condition is asthma (an increasingly prevalent and worrying problem), in which the peripheral parts of the lung, namely those tiny airways and air spaces known respectively as bronchioles and alveoli, constrict to restrict the flow of air therethrough.
In other lung conditions the lung""s small peripheral arteriesxe2x80x94the pulmonary arteriesxe2x80x94also constrict, typically those deep in the lungs where the oxygen tension falls as in an asthmatic attack, pneumonia, or chronic lung diseases like bronchitis and emphysema (and it should also be noted that such constriction often occurs without the causative mechanism being fully explained; this is the so-called primary pulmonary hypertension).
The most effective treatments for asthma and like conditions involve the inhalation as an aerosol of some suitable chemical agent in normally inhaled air. At present, to deal with the problem of constricted small pulmonary arteries only a few relieving substances are known, and one of the most powerfulxe2x80x94that known as prostacyclin, an extremely potent vasodilatorxe2x80x94has to be administered on a continuous basis by infusion into a vein and so to the pulmonary arteries.
The aforementioned British and International Specifications relate to the use of nitric oxide (NO), another well-known and effective dilating agent for treating both lung problems of the blood-vessel-constriction type and of the asthma airway type. More specifically, these Specifications concern the manner in which nitric oxide is administered, and the apparatus used for this administration; they propose that the nitric oxide be administered to the Patient not continuously (either in admixture with, or separately but side by side with a supply of, air, oxygen or oxygen-enriched air) but intermittently and in short pulses of known, pre-determined volume at one or more suitable time during each inhalation. In the treatment of the constriction of the small pulmonary arteries the very short pulse, or spike, of nitric oxide is provided at the start of the inhalation, such that the resultant bolus of nitric oxide mixture inhaled by the Patient has a nitric oxide concentration high enough to have the desired therapeutic effect, even if admixed with some additional air, but is of such short duration (both in time and, as a result, in physical length) that, pushed by the following much larger volume of plain, and therefore nitric oxide-free, air/oxygen, it reaches deeper into the lungs, where it both acts on the small pulmonary arteries and is taken up into the capillaries to react with haemoglobin (so preventing the formation of nitrogen dioxide). By contrast, in the treatment of asthma-like airway diseases or conditions the very short pulse of nitric oxide is timed to fall just before the end of the inhalation. This leaves the nitric oxide in contact with the airway smooth muscle in sufficient concentration to cause relaxation, but because at the end of the inhalation the airway is flushed of all the nitric oxide by the air coming from alveoli and lung periphery, so there is avoided prolonged exposure with the consequent risk of the formation of toxic nitrogen dioxide.
This previous invention concerns the administration of nitric oxide. The present invention stems from the appreciation that the same controlled breathing-related xe2x80x9cpulsatilexe2x80x9d delivery to the Patient""s lungs can be usefully employed with many other medicaments; the invention is thus treatment apparatusxe2x80x94and in particular small (pocket-sized) hand-held apparatusxe2x80x94that utilises the xe2x80x9cspikexe2x80x9d principle. More specifically, the invention proposes apparatus for the delivery of a medicamentxe2x80x94a drug, which can be in liquid or in solid (powder) formxe2x80x94into the Patient""s lungs in the form of a bolus, pulse, or spike of the medicament entrained in and driven by the normal respiration air, which apparatus comprises in essence a drug dispenser (which might be a conventional liquid-dispensing nebuliser or a dry-powder dispenser, in the reservoir of which is stored the medicament to be administered), driven by some suitable pressurised gas from a completely separate valved cylinder thereof to deliver an aerosol cloud of medicament into a tube through which the Patient is breathing (by mouth) normal air, the gas cylinder valve being controlled by a suitably programmed computing device that is fed data describing the pressure within the breathing tube and so is able to open and close the valve at and for a time such as to drive the drug dispenser to deliver (to the tube and thence to the Patient""s lungs) a required pulse of medicament at any selected point within the Patient""s respiratory cycle. The provision of pulses of medicament is not in itself unknown, and one typical case is the asthma-treatment device the subject of Aradigm (Goodman et al) U.S. Pat. No. 5,404,871, which described an inhaler wherein a computer suitably controls the delivery of a medicament from a propellant-driven reservoir thereof. However, using a combination propellant/medicament source like that makes it quite difficult fully to control the manner in which the medicament is delivered to the Patient; the present invention deals in part with this by having the medicament reservoir and the driving gas source completely separate.
In one aspect, therefore, the invention provides miniature, pocket-sized, hand-holdable apparatus for the delivery of a medicament into the Patient""s lungs in the form of a bolus, pulse, or spike of the medicament entrained in and driven by the normal respiration air, which apparatus comprises:
a tube through which the Patient is able to breath (by mouth) normal air;
a drug dispenser (in the reservoir of which is storable the medicament to be administered) the output of which is deliverable into the tube for inhalation by the Patient;
separate from the dispenser, a valved cylinder for a suitable pressurised gas, which cylinder is operatively connectable to the dispenser so as in use to drive the dispenser to deliver an aerosol cloud of medicament into the tube;
pressure sensing means located within or operably connected to the tube, and able to provide data about the air pressure therewithin, and thus about the Patient""s respiratory cycle; and
programmed computing means operatively connectable to the gas cylinder valve so as to be able to open and shut that valve, and able to receive pressure data from the pressure sensing means;
such that the computing means can utilise the pressure data to enable the gas cylinder to drive the dispenser to deliver (to the tube and thence to the Patient""s lungs) a required pulse of medicament at any selected point within the Patient""s respiratory cycle.
The apparatus of this invention is intended to be portable. Indeed, it is the primary purpose of the invention to provide the apparatus in light, pocket-sized form small enough to be held in the hand, and to be used while being so held, and accordingly, hereinafter the apparatus is described in terms most appropriate for such a small hand-held piece of kit.
The invention provides apparatus for the delivery of a medicament into the Patient""s lungs. The medicament can be any such material that might need to be administered to the lungs. For example, to treat asthma the medicament could be a bronchodilator such as SALBUTAMOL or TERBUTALINE or a steroid such as BECLOMETHASONE or FLIXOTIDE, while to treat an actual lung infection the medicament might be an antibiotic such as TICARCILLIN or COLISTIN.
The medicament may be formulated in any way that is both appropriate to the active ingredient of the medicament and to the need to have it turn into an aerosol spray in use. It may be presented as a solution or suspension in some liquidxe2x80x94water, perhapsxe2x80x94or it may even be supplied as a fine powder, possibly with or absorbed onto a powder carrier (when in a liquid form the drug is delivered to the Patient as an aerosol of fine droplets; when in solid/powder form it is delivered as a cloud of dust particles). By way of example, the asthma-treating medicament FLIXOTIDE is conveniently used in the form of dry powder, while the sputum lytic agent rhDNAse is advantageously delivered in the form of a liquid aerosol (droplets of liquid suspended in gas).
The invention""s apparatus delivers its medicament into the lungs in the form of a bolus, pulse, or spike of the medicament entrained in and driven by the normal respiration air. The idea of this is simply to ensure that a high proportion of the medicament reaches and affects the target area and the target area only, rather than having the whole of the lungs subjected to it. The smaller the bolusxe2x80x94the shorter the pulsexe2x80x94the better this specificity is achieved. In some cases the pulse will be very short indeed, and while it is difficult to define precisely what is meant by xe2x80x9cveryxe2x80x9d short, the following comments may be of assistance. The term xe2x80x9cvery shortxe2x80x9d means primarily that the provision of sufficient medicament for each bolus thereof is achieved by supplying the driving gas for a time periodxe2x80x94of the order of a few tens of millisecondsxe2x80x94that is very short compared with the length of an average inhalation (which is about 1.5 second). However, there is more to the shortness of the pulse than just its temporal duration, for, the purpose of the pulse being to provide a bolus of medicament both of relatively high concentration and of relatively short physical length, both the actual flow rate of the medicament (perhaps in its carrier mixture form) as it is fed to the Patient and also the actual concentration of the medicament in that fed gas are important factors. What has been determined by experiment is that very satisfactory results are obtained using pulse durations of a few tens of milliseconds, and typically 20 to 30 msec. Thus, while it will clearly be understood that what is a xe2x80x9cvery shortxe2x80x9d pulse depends upon the flow rate and concentration of the administered medicament, nevertheless it can now be said that the term xe2x80x9cvery shortxe2x80x9d means xe2x80x9cof the order of a few units or tens of millisecondsxe2x80x9d. Or, to put it another way, the term means roughly one thousandth of the length of an average inhalation.
In the apparatus of the invention the medicament is. driven into the Patient""s lungs through a tube through which the Patient is breathing (by mouth) normal air. This tube is essentially nothing more than a short open-ended hollow cylinderxe2x80x94say, 5 in (13 cm) long and 1 in (2.5 cm) external diameterxe2x80x94possibly with a flattened mouthpiece to make it more convenient for the Patient to use, and nothing more need be said about it here.
The apparatus of the invention incorporates a drug dispenser in the reservoir of which is storable the medicament to be administered. It is the output of the dispenser which is deliverable into the tube for inhalation by the Patient.
One form of drug dispenser is the conventional nebuliser. Nebulisersxe2x80x94xe2x80x9ccloud-formersxe2x80x9dxe2x80x94are in general well-known items of equipment, commonly encountered in scent sprays, aerosol sprays, and carburettors, and little need be said about them here. Even so, it is convenient to note that a nebuliser is a basically a reservoir that has a fine orifice through which its contents may exit and across which is blown a stream of gas along a pipeway. As the gas flows past the orifice it causes an external pressure drop (relative to the reservoir""s internal pressure: this pressure drop can be enhanced by shaping the pipeway as a Venturi constriction at the appropriate position), and so some of the reservoir""s contents is xe2x80x9csuckedxe2x80x9d out into the gas stream and breaks up into an aerosol-like cloud of drops or particles that is then swept along the pipeway by the:driving gas. It is convenient to include within the pipeway downstream of the orifice an obstacle, or baffle, that is positioned within the path of the emerging drop/particle stream so as to impede all but the smallest drops/particles, which smallest ones are of a size most appropriate to being transported to the farthest reaches of the lung. For a small hand-held device the nebuliser is conveniently around 2.5 in (6 cm) long and an inch (2.5 cm) or so across, the reservoir holding perhaps 1.5 cu. in (25 cc) of medicament formulation.
An alternative form of dispenser is the dry-powder dispenser, another well-established piece of equipment in which fine particles of medicament are held without liquid (indeed in some cases are created at the time of use by abrasion of a solid or compacted tablet) and are caused to enter the inspired airstream.
The drug dispenser (of whatever sort) employed in the invention""s apparatus is driven by a suitable gas from a valved cylinder thereof, so as to produce the desired aerosol cloud of medicament and drive it into the tube. This gas can be simply a carrierxe2x80x94thus, an effectively inert (to the Patient) gas such as carbon dioxide or nitrogenxe2x80x94but it may be advantageous if the gas itself have some suitable medicinal action. For example, the gas might well be nitrous oxide (N2O). There is little else to say about this, save that gas in the cylinder is likely to be at a high pressure, and so should be regulated to provide a lower, and constant, pressure appropriate to the operation of the dispenser, and save also that the gas cylinder (and any regulating means) should clearly be of a size and strength suitable to its intended purposexe2x80x94and for a hand-held device an appropriate size is, much like the drug dispenser, around 3 in (7.5 cm) long and an inch (2.5 cm) or so across, and holding perhaps 2 cu. in (35 cc) of liquified gas under a pressure of 50 bar (3 MPa, or 700 lbs/sq. in).
The cylinder is, of course, a valved cylinder, and the operation of the valve is controlled by the computing means (via some suitable actuating means) in response to the computing means"" programming and input from the pressure sensor. The valve mechanism may take any appropriate formxe2x80x94it is typically an electromagnetically-actuated device such as one of those miniature solenoid valves available from Parker Hannifin Corp., Pneutronics Div., Hollis, N.H., USA, and is conveniently powered from the computing means"" power source.
The invention""s apparatus includes pressure sensing means located within or connectable to the tube, and in use providing the computing means with data about the air pressure therewithin, and thus about the Patient""s respiratory cycle. The sensor may be any suitable pressure-detecting transducer with an electrical output, and one preferred sensor is that available under the designation 24/26 PC from Honeywell Inc., Freeport, Ill., USA.
Controlling the whole operation of the medicament administering apparatus of the invention is the programmed computing means. This is operatively connectable to the gas cylinder valve (via its actuating means) so as to be able to open and shut that valve, it receives pressure data from the pressure sensing means so that it xe2x80x9cknowsxe2x80x9d at all times the progress of the Patient""s respiratory cycle, and it is programmed to make use of that information so as to enable the gas cylinder to drive the drug dispenser to deliver (to the tube and thence to the Patient""s lungs) a required pulse of medicament at any selected point within that cycle. Notionally, the computing means could be a general purpose microcomputer appropriately programmed and able to deal with the relevant inputs and outputs from and to the real world. In practice, though, the computing means is most advantageously a simple single chip computer xe2x80x9chard wiredxe2x80x9d, or programmed in ROM, to take the relevant actions. Such a computer can be no more than 2 in (5 cm) or so long and wide, and 0.5 in (1.25 cm) deep, and can run off a small battery. It is ideally suited for use in a hand-held medicament-delivery system.
The programmed computing means takes the pressure data and in accordance with its program makes use of that information so as to enable the gas cylinder to drive the drug dispenser to deliver (to the tube and thence to the Patient""s lungs) a required pulse of medicament at any selected point within that cycle. Which point that is, and for how long the pulse will last, is dependent upon the Patient""s illness and the medicament being taken (this has been touched upon hereinbefore). The treatment of some conditions might require very short pulses to be delivered right at the beginning of the inspiration phase of the respiratory cyclexe2x80x94as the Patient draws in the next breathxe2x80x94while in contrast the treatment of others might require rather longer pulses to be delivered at the end of the inspiration phase of the respiratory cyclexe2x80x94as the Patient finishes inhaling the present breath and just before the exhale starts.
The primary purpose of the programmed computing means is to control the dispensing of the relevant medicament in dependence upon the respiratory data it receives, and in this connection the operation of the dispenser may be improved if the computing means utilises an algorithm to optimize the detection of the breathing cycle in the presence of artefacts. In addition, however, the computing means can usefully gather data about the patient""s respiration, and about apparatus usage and drug-dispenser changes, and then compute (and present) details of the patient""s respiratory statistics, and so on. Moreover, it may be desirable to provide additional control of apparatus usage in accordance with data that may be pre-programmed into the apparatus or even encoded on (and read off) the drug container, or computed from the detected patient breathing cycle. Additionally, it may be desirable to enable the prevention of drug delivery in the absence of appropriate User/Patient identification by means of button/keyboard interaction. Accordingly, preferred embodiments of the medicament delivery apparatus of the invention include the following:
A coding system (whether optical, electrical or by physical shape or other means) by which the contents of the drug container and the date limits of its contents may be detected by the programmed computing means and. reported to the user, or employed in the control of the drug-dispensing process.
A visual or audible display system in which information may be provided to the User on the operation of the device, the status of the drug container or the parameters of their breathing process as measured by the. pressure-sensing means and computed by the programmed computing means.
A means whereby the User may provide information to the programmed computing means, typically one or more electrical buttons or a miniature keypad.

Abstract: The present invention proposes treatment apparatusxe2x80x94specifically and in particular small (pocket-sized) hand-held apparatusxe2x80x94that utilises the xe2x80x9cspikexe2x80x9d principle. It suggests apparatus for the delivery of a medicament into the Patient""s lungs in the form of a bolus, pulse, or spike of the medicament entrained in and driven by the normal respiration air, which apparatus comprises a drug dispenser (that in essence may be a conventional nebuliser or a dry-powder delivery system 11), in the reservoir (12) of which is stored the medicament to be administered, driven by some suitable pressurised gas from a valved cylinder (18) thereof to deliver an aerosol cloud of medicament into a tube (103) through which the Patient is breathing (by mouth) normal air, the gas cylinder valve (19) being controlled by a suitably programmed computing device (101) that is fed data describing the pressure within the breathing tube (103) and so is able to open and close the valve (19) at and for a time such as to drive the dispenser (11) to deliver (to the tube and thence to the Patient""s lungs) a required pulse of medicament at any selected point within the Patient""s respiratory cycle.